CABA-201 is named as a drug or biological intervention in 4 clinical trials in our USA trial register, 4 of which are recruiting. The lead sponsor is Cabaletta Bio. Registered phases: Phase 1/2 and Phase 2/3. Conditions studied include Systemic Lupus Erythematosus; Lupus Nephritis; Pemphigus Vulgaris.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Systemic Lupus Erythematosus | 1 |
| Lupus Nephritis | 1 |
| Pemphigus Vulgaris | 1 |
| Systemic Sclerosis | 1 |
| Scleroderma | 1 |
| Interstitial Lung Diseases | 1 |
| Generalized Myasthenia Gravis (gMG) | 1 |
| Lead sponsor | Trials |
|---|---|
| Cabaletta Bio | 4 |
| Register | CABA-201 trials |
|---|---|
| Clinical trials in USA | 4 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how CABA-201 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists CABA-201 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.